Current Trends in the Diagnosis and Evidence-Based Management of Patients with Myeloproliferative Disorders
Abstract
Myeloproliferative disorders (MPD) are clonal hematopoietic disorders characterized by abnormal clone expansion of haematological progenitor cells, which can lead to thrombosis, bleeding, and/or transformation to leukaemia. Chronic myelogenous leukaemia (CML) is characterised by increasing granulocytic cell proliferation with no loss of differentiation, leading to an increased number of granulocytes and their immature progenitors, with occasional blast cells on peripheral blood film. Polycythaemia Vera (PV) is a disorder of stem cells that presents a total hyperplasia, malignant, and cancerous marrow. Its most prominent feature is an increased absolute red blood cell mass due to uncontrolled red blood cell production, followed by increased myeloid and megakaryocytic production due to an abnormal clone of the haematopoietic stem cells with increased sensitivity to growth factors. Essential thrombocythemia (ET) is defined by a persistent increase in platelet count with a proclivity for thrombosis and haemorrhage. Expansion of megakaryocytes in the cell lineage leads to high platelet count, and the condition is thought to be clonal. Primary myelofibrosis (PMF) results in aberrant megakaryocyte development. Extramedullary haematopoiesis and reactive connective tissues are found in fully mature bone marrow (BM). PMF is linked to uncontrolled megakaryopoiesis as well as atypical, fibrosis, and hypercellularity. Haematological and morphological abnormalities in combinations with mutations (BCR-ABL, CARL, JAK2 or MPL) represent major diagnostic criteria for MPD. The WHO criteria for tumours of the hemopoietic and lymphoid tissues was revised in 2016. Prognostic models rely on clinical and haematological data, but new models with genetic information are being created for clinical trial environments. Management of most patients with MPDs involves treatment or monitoring symptoms associated with presenting disease and/or preventing other events such as thrombosis. Treatment modalities include symptomatic treatments, surgery, therapeutic radiation, therapeutic phlebotomy, therapeutic apheresis, cytoreductive therapy and haematopoietic stem cells transplantations.
Downloads
References
Abu-Zeinah, G., Krichevsky, S., Cruz, T., et al. (2021). Interferon-alpha for treating polycythaemia vera yields improved myelofibrosis-free and overall survival. Leukaemia, 35 (9), 259-2601.
Angermayr, B., Cejna, M., Schoder, M., et el. (2002) Transjugular intrahepatic portosystemic shunt for treatment of portal hypertension due to extramedullary haematopoiesis in idiopathic myelofibrosis. Blood, 99,4246–4247.
Apperley, J. F., Cortes, J. E., Kim, D. W., et al. (2009). Dasatinib in the treatment of chronic myeloid leukaemia in accelerated phase after imatinib failure: the START a trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 27 (21), 3472–3479.
Arber, D. A., Orazi, A., Hasserjian, R., et al. (2016). The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukaemia. Blood, 127 (20), 2391-2405.
Ashorobi, D., & Gohari, P. (2021). Essential Thrombocytosis. Retrieved November 17, 2021, from https://www.ncbi.nlm.nih.gov/books/NBK539709/
Alvarez-Larran, A., Abraldes, J.G., Cervantes, F., et al. (2005) Portal hypertension secondary to myelofibrosis: a study of three cases. American Journal of Gastroenterology, 100, 2355–2358.
Barbu, T., Barosi, G., Birgegard, G., et al. (2011). Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. Journal of Clinical Oncology, 29 (6), 761-770.
Barbui, T., Thiele, J., Gisslinger, H., et al. (2014). Masked polycythaemia vera (mPV): results of an international study. American Journal Hematology, 89 (1), 52-54.
Barosi, G., Ambrosetti, A., Buratti, A., et al. (1993) Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction. Leukemia,7, 200–206.
Barosi, G., Ambrosetti, A., Centra, A., et al. (1998) Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Blood, 91, 3630–3636.
Barosi, G., Bergamaschi, G., Marchetti, M., et al. (2007) JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood, 110, 4030–4036.
Barosi, G., Mesa, R.A., Thiele, J., et al. (2008) Proposed criteria for the diagnosis of post-polycythaemia and post-essential thrombocythemia myelofibrosis: a consensus statement from the Onternational Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Leukemia, 22, 437–438.
Bartlett, R.P., Greipp, P.R., Tefferi, A., et al. (1995) Extramedullary haematopoiesis manifesting as a symptomatic pleural effusion. Mayo Clinical Proceedings,70, 1161–1164.
Baxter, E.J., Scott, L.M., Campbell, P.J., et al. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 365(9464), 1054–1061.
Beer, P.A., Campbell, P.J. & Green, A.R. (2010) Comparison of different criteria for the diagnosis of primary myelofibrosis reveals limited clinical utility for measurements of serum lactate dehydrogenase. Haematologica, 95, 1960–1963.
Beer, P.A., Erber, W.N., Campbell, P.J. et al. (2011) How I treat essential thrombocythemia. Blood,117, 1472–1482.
Bellanne-Chantelot, C., Chaumarel, I., Labopin, M, et al. (2006). Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood, 108, 346-352.
Berk, P. D., Goldberg, J. D., Donovan, P. B., et al. (1986). Therapeutic recommendations in polycythaemia vera based on Polycythaemia Vera Study Group protocols. Seminar Hematology, 23 (2), 132-143.
Besa, E. C., Grethlein, S. J., Seiter, K., et al. (2021). Drugs & Diseases>Hematology. Retrieved November 11, 2021, from Medscape: emedicine.medscape.com
Besses, C., & Alvarez-Larrán, A. k. (2016). How to Treat Essential Thrombocythemia and Polycythaemia Vera. Clinic Lymphoma Myeloma Leukemia, 16, 114-123.
Bewersdorf, J. P., Giri, S., Wang, R., et al. (2021). Interferon alpha therapy in essential thrombocythemia and polycythaemia vera-a systematic review and meta-analysis. Leukemia, 35 (6), 1643-1660.
Bleeker, J. S., & Hogan, W. J. (2011). Thrombocytosis: diagnostic evaluation, thrombotic risk stratification, and risk-based management strategies. Thrombosis, 2016, 1-16.
Bose, P., & Verstovsek, S. (2017). JAK2 inhibitors for myeloproliferative neoplasms: what is next? Blood, 130 (2), 115-125.
Bouabdallah, R., Coso, D., Gonzague-Casabianca, L., et al. (2000) Safety and efficacy of splenic irradiation in the treatment of patients with idiopathic myelofibrosis: a report on 15 patients. Leukaemia Research, 24, 491–495.
Brière, J. B. (2007). Essential thrombocythemia. Orphanet journal of rare diseases, 23, 2-3.
Cabagnols, X., Favale, F., Pasquier, F., et al. (2016). Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. Blood, 127 (3), 333-342.
Campbell, P., & Green, A. R. (2005). Management of polycythaemia vera and essential thrombocythemia. Hematology American Society Hematology Education Program, 201-208.
Campbell, P.J. & Green, A.R. (2006) The myeloproliferative disorders. New England Journal of Medicine, 355, 2452–2466.
Campbell, P.J., Griesshammer, M., Döhner, K., et al. (2006) V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood,107, 2098–2100.
Chang, J.C. & Gross, H.M. (1988) Remission of chronic idiopathic myelofibrosis to busulfan treatment. American Journal of Medical Science,295, 472–476.
Cervantes, F. (2011). Management of essential thrombocythemia. American Society Hematology Education Program, 2011, 215-221.
Cervantes, F., Dupriez, B., Pereira, A., et al. (2009). New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood, 113 (13), 2895-2901.
Chait, Y., Condat, B., Cazals-Hatem, D., et al. (2005). Relevance of the criteria commonly used to diagnose myeloproliferative disorders in patients with splanchnic thrombosis. British Journal Haematology, 129, 553-560.
Chul, W. C., Soo-Mee, B., Seongsoo, J., et al. (2015). Guidelines for the management of myeloproliferative neoplasm. Korean Journal Internal Medicine, 30 (6), 771-788.
Clodagh, K., Deepti, H. R., & C, H. N. (2013). Treatment and management of myelofibrosis in the era of JAK inhibitors. Biologics, 7, 189–198.
Cortelazzo, S., Finazz, I. G., Ruggeri, M., et al. (1995). Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. New England Journal Medicine, 332 (17), 1132-1136.
Cortes, J. E., Kantarjian, H., Shah, N. P., et al. (2012). Ponatinib in refractory Philadelphia chromosome-positive leukemias. The New England journal of medicine, 367 (22), 2075–2088.
Cortes, J. E., Kim, D. W., Pinilla-Ibarz, J., et al. (2013). A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. The New England journal of medicine, 369 (19), 1783-1796.
Cortes, J., Giles, F., O'Brien, S., et al. (2003). Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukaemia after failure of interferon-alpha. Blood, 102 (1), 83–86.
Cortes, J., Kim, D. W., Raffoux, E., et al (2008). Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukaemia in blast phase. Leukemia, 22 (12), 2176–2183.
Cortes, J., Quintas-Cardama, A., Jones, D., et al. (2011). Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukaemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating fact. cancer, 117 (3), 572–580.
Doki, N., Irisawa, H., Takada, S., et al. (2007) Transjugular intrahepatic portosystemic shunt for the treatment of portal hypertension due to idiopathic myelofibrosis. Internal Medicine,46, 187–190.
Elliot, M.A., Chen, M.G., Silverstein, M.N. et al. (1998) Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. British Journal of Haematology,103, 505–511.
Epstein, E., & Goedel, A. (1934). Hemorrhagic thrombocythemia with a cascular, sclerotic spleen. Virchows Arch, 293, 233-248.
Faoro, L.N., Tefferi, A. & Mesa, R.A. (2005) Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia. European Journal of Haematology.74, 117–120.
Feldman, L.S., Demyttenacre, S.V., Polyhronopoulos, G.N.et al. (2008) Refining the selection critieria for laparoscopic versus open splenectomy for splenomegaly. Journal of Laparoendoscopic and Advanced Surgical Techniques,18,13–19.
Fruchtman, S. M., Mack, K., Kaplan, M. E., et al. (1997). From efficacy to safety: a Polycythaemia Vera Study Group report on hydroxyurea in patients with polycythaemia vera. Seminar Hematolgy, 34 (1), 17-23.
Fruehauf, S., Topaly, J., Buss, E. C., et al. (2007). Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukaemia in myeloid blast crisis. Cancer, 109 (8), 1543-1549.
Gambacorti-Passerini, C., Antolini, L., Mahon, F. X., et al. (2011). Multicenter independent assessment of outcomes in chronic myeloid leukaemia patients treated with imatinib. J Natl Cancer Inst, 103 (7), 553-561.
Gambacorti-Passerini, C., Kantarjian, H. M., Kim, D.-W., et al. (2015). Long-term efficacy and safety of bosutinib in patients with advanced leukaemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. American journal of hematology, 90 (9), 755-768.
Giles, F. J., le Coutre, P. D., Pinilla-Ibarz, J., et al. (2013). Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukaemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia, 27 (1), 107-112.
Guglielmelli, P., Barosi, G., Specchia, G., et al. (2009) Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood, 114, 1477–1483.
Guglielmelli, P., Biamonte, F., Score, J., et al. (2011) EZH2 mutational status predicts poor survival in myelofibrosis. Blood, 188, 5227–5234.
Harrison, C. (2005). Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. British Journal Haematology, 129, 293-306.
Hehlmann, R., Lauseker, M., Jung-Munkwitz, S., et al. (2011). Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukaemia. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 29 (12), 1634–1642.
Heuck, G. (1879). Two cases of leukaemia with peculiarblood and bone marrow findings, respectively. Arch Pathol Ana, 78, 475-496.
Hughes, T. P., Branford, S., White, D. L., et al. (2008). Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood, 112 (10), 3965-3973.
Ianotto, J.-C., Kiladjian, J.-J., Demory, J.-L., et al. (2009) PEG-IFN-α-2a therapy in patients with myelofibrosis: a study of the French Groupe d'Etudes des Myelofibroses (GEM) and France Intergroupe des Syndromes Myéloprolifératifs (FM). British Journal of Haematology, 146, 223–225.
Imbert, M., Pierre, R., Thiele, J., et al. (2001). Essential thrombocythaemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editor. World Health Organization Classification of Tumours Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, IARC press.
Jabbour, E., Kantarjian, H., Cortes, J., et al. (2007) PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer, 110, 2012–2018.
Jain, P., Kantarjian, H., Nazha, A., et al. (2013). Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukaemia: results with four tyrosine kinase inhibitor modalities. Blood, 121 (24), 4867–4874.
James, C., Ugo, V., Le Couédic, J.P., et al. (2005). A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature,434(7037),1144–1148.
Jelinek, J., Oki, Y., Gharibyan, V., et al. (2005). JAK2 mutation 1849G >T is rare in acute leukemias but can be found in CMML, Philadelphia-chromosome negative CML and megakaryocytic leukaemia. Blood, 106, 3370-3373.
Johansson, P. (2006). Epidemiology of the myeloproliferative disorders polycythaemia vera and essential thrombocythemia. Seminars Thrombosis Hemostasis, 32, 171-173.
John, T. R., Philip, A., Beer, M. B., et al. (2012). Guideline for the diagnosis and management of Myelofibrosis. British Journal Haematology, 158 (4), 453-471.
Kantarjian, H. M., Cortes, J., O’Brien, S., et al. (2002). Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukaemia in blast phas. Blood, 99 (10), 3547–3553.
Kantarjian, H., Talpaz, M., O’Brien, S., et al. (2004). High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukaemia. Blood, 103 (8), 2873–2878.
Kaushansky, K. (2005). On the molecular origins of the chronic myeloproliferative disorders: it all makes sense. Blood, 105, 4187-4190.
Kondo, T., Okabe, M., Sanada, M., et al. (1998). Kondo T, Okabe M, Sanada M, Kurosawa M, Suzuki SFamilial essential thrombocythemia associated with one-base deletion in the 5'-untranslated region of the thrombopoietin gene. Blood, 92, 1091-1096.
Kralovics, R., Passamonti, F., Buser, A. S., et al. (2005). A gain of function mutation of JAK2 in myeloproliferative disorders. New England Journal Medicine, 352, 1779-1790.
Kupferschmid, J.P., Shahian, D.M. & Villanueva, A.G. (1993) Massive hemothorax associated with intrathoraxic extramedullary haematopoiesis involving the pleura. Chest,103, 974–975.
Landolfi, R., Colosimo, C., De Candia, E., et al. (1988) Meningeal haematopoiesis causing exophthalmos and hemiparesis in myelofibrosis: effect of radiotherapy. Cancer, 62, 2346–2349.
Lange, T., Gunther, C., Kohler, T., et al. (2003). High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML. Blood, 101 (6), 2152–2155.
Leinweber, C., Order, S.E. & Calkins, A.R. (1991) Whole-abdominal irradiation for the management of gastrointestinal and abdominal manifestations of agnogenic myeloid metaplasia. Cancer, 68, 1251–1254.
Levine, R.L., Wadleigh, M., Cools, J., et al. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythaemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 7(4),387–397.
le Coutre, P., Kreuzer, K. A., Pursche, S., et al. (2004). Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer chemotherapy and pharmacology, 53 (4), 313–323.
Lipton, J. H., Chuah, C., Guerci-Bresler, A., et al. (2014). A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML). Blood, 124 (21), 519–519.
Löfvenberg, E. & Wahlin, A. (1988) Management of polycythaemia vera, essential thrombocythaemia and meylofibrosis with hydroxyurea. European Journal of Haematology, 41, 375–381.
López-Guillermo, A., Cervantes, F., Bruguera, M., et al. (1991) Liver dysfunction following splenectomy in idiopathic myelofibrosis: a study of 10 patients. Acta Haematologica, 85, 184–188.
Lu, X., & Chang, R. (2021). Polycythaemia Vera. Treasure Island: StatPearls Publishing.
Manoharan, A. & Pitney, W.R. (1984) Chemotherapy resolves and reverses marrow fibrosis in myelofibrosis. Scandinavian Journal of Haematology,33, 453–459.
Marchioli, R., Guido, F., Giorgina, S., Rossella, C., et al. (2013). CYTO-PV Collaborative Group. Cardiovascular events and intensity of treatment in polycythaemia vera. New England Journal Medicine, 368 (1), 22-33.
Martinez-Trillos, A., Gaya, A., Maffioli, M., et al. (2010) Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Annals of Hematology, 89, 1233–1237.
McMullin, M. F., Wilkins, B. S., Harrison, C. N., et al. (2015). Management of polycythaemia vera: a critical review of current data. British Journal Haematology.
Mesa, R.A., Steensma, D.P., Pardanani, A., et al. (2003) A phase 2 trial of combination low-dose thalidomide and prednisolone for the treatment of myelofibrosis with myeloid metaplasia. Blood,101, 2534–2541.
Michiels, J. J., Kutti, J., & Stark, P. (1999). Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythaemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis. Netherland Journal Medicine, 54 (2), 46-62.
Michiels, J. J., Berneman, Z., Schroyens, W., et al. (2004). Philadelphia (Ph) chromosome-positive thrombocythemia without features of chronic myeloid leukaemia in peripheral blood: natural history and diagnostic differentiation from Ph negative essential thrombocythemia. Annal Hematology, 83, 504-512.
Mossuz, P. (2006). Groupe d'Etudes Multicentriques des Syndrome MyeloProliferatifs (GEMSMP) Influence of the assays of endogenous colony formation and serum erythropoietin on the diagnosis of polycythaemia vera and essential thrombocythemia. Seminars Thrombosis Hemostasis, 32, 246–250.
Murphy, S., Peterson, P., Illand, H., Lazlo, J., et al. (1997). Seminars Hematology, 34, 29-39.
National Cancer Institute, P. (2020). Myeloproliferative Neoplasms Treatment. National Cancer Institute. Retrieved Novemver 10, 2021, from http://www.cancer.gov/types/myeloproliferative/hp/chronic-treatment-pdq
Neben-Wittich, M.A., Brown, P.D. & Tefferi, A. (2010) Successful treatment of severe extremity pain in myelofibrosis with low-dose single-fraction radiation therapy. American Journal of Hematology, 85, 808–810.
Nowell PCHD. (1960). A inute chromosome in human chronic granulocytic leukaemia.Science, 132 (1497), 1.
O’Brien, S. G., Guilhot, F., & Larson, R. A. (2003). Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia. The New England Journal of Medicine, 348 (11), 994–1004.
Oh, S. T., Simonds, E. F., Jones, C.,et al. (2010). Blood, 116 (6), 988-992.
Ohanian, M., Kantarjian, H. M., Quintas-Cardama, A., et al. (2014). Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukaemia in accelerated phase. Clinical lymphoma, myeloma &leukemias, 14 (2), 155–162.
Osler, W. (1903). Chronic cyanosis with polycythaemis and enlarged spleen: a new entity. American Journal Medical Science, 126, 187-192.
Pardanani, A.D., Levine, R.L., Lasho, T., et al. (2006) MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood, 108, 3472–3476.
Petti, M.C., Latagliata, R., Spadea, T., et al. (2002) Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. British Journal of Haematology,116, 576–581.
Pikman, Y., Lee, B.H., Mercher, T., et al. (2006) MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Medicine, 3, e270.
Price, F. & Bell, H. (1985) Spinal cord compression due to extramedullary haematopoiesis. Successful treatment in a patient with long standing myelofibrosis. JAMA,253, 2876–2877.
Preudhomme, C., Guilhot, J., Nicolini, F. E., et al. (2010). Imatinib plus peginterferon alfa-2a in chronic myeloid leukaemia. The New England journal of medicine, 363 (26), 2511–2521.
Riesterer, O., Gmür, J. & Lütolf, U. (2008) Repeated and preemptive palliative radiotherapy of symptomatic hepatomegaly in a patient with advanced myelofibrosis. Onkologie,31, 325–327.
Rowley, J. D. (1973). Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. Nature, 243 (5405), 290–293.
Sacchi, S., Kantarjian, H. M., O’Brien, S., et al. (1999). Chronic myelogenous leukaemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer, 86 (12), 2632–2641.
Sawyers, C. L., Hochhaus, A., Feldman, E., et al. (2002). Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukaemia in myeloid blast crisis: results of a phase II study. Blood, 99 (10), 3530–3539.
Scott, L. M., Tong, W., Levine, R. L.,et al. (2007). New England Journal Medicine, 356 (5), 459-468.
Simonsson, B., Gedde-Dahl, T., Markevarn, B.,et al. (2011). Combination of pegylated IFN-alpha2b with alpha imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukaemia. Blood, 118 (12), 3228–3235.
Spivak, J. L., & Silver, R. T. (2008). The revised World Health Organization diagnostic criteria for polycythaemia vera, essential thrombocytosis and primary myelofibrosis: an alternative proposal. Blood, 112 (2), 231-239.
Srikanth, N., & Sara, J. G. (2021, September 20). Polycythaemia Vera. Retrieved November 15, 2021, from https://emedicine.medscape.com/article/205114-print
Steensma, D.P., Hook, C.C., Stafford, S.L. et al. (2002) Low-dose, single fraction, whole-lung radiotherapy for pulmonary hypertension associated with myelofibrosis and myeloid metaplasia. British Journal of Haematology,118, 813–816.
Streiff, M. B., Smith, B., & Spivak, J. L. (2002). The diagnosis and management of polycythaemia vera in the era since the Polycythaemia Vera Study Group: a survey of American Society of Hematology members' practice patterns. Blood, 99 (4), 1144-1149.
Sung-Yong, K., Sung, H. B., Soo-Mee, B., et al. (2020). The 2020 revision of the guidelines for the management of myeloproliferative neoplasms. The Korean Journal of Internal Medicine, 319, 2-18.
Swerdlow, S. H., Campo, E., Harris, N. L., et al. (2008). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4 ed.). Lyon: International Agency for Research on Cancer.
Szpurka, H., Tiu, R., Murugesan, G., et al. (2006). Refractory anemia with ringed sideroblasts associted with marked thrombocytosis (RAR-T), another myeloproliferative condition characterised by JAK2 V617F mutation. Blood, 108, 2173-2181.
Tefferi, A., Mesa, R.A., Nagomey, D.N., et al. (2000) Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood,95, 2226–2233.
Tefferi, A., Elliot, M.A., Yoon, S.Y., et al. (2001a) Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia. Blood,97, 1896.
Tefferi, A., Jiménez, T., Gray, L.A., et al. (2001b) Radiation therapy for symptomatic hepatomegaly in myelofibrosis with myeloid metaplasia. European Journal of Haematology,66, 37–42.
Tefferi, A., Lasho, T.L., Schwager, S.M., et al. (2005) The JAK2 (V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. British Journal of Haematology, 131, 320–328.
Tefferi, A., Barosi, G., Mesa, R.A., et al. (2006a) International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood,108, 1497–1503.
Tefferi, A., Cartes, J., Verstovsek, S., et al. (2006b) Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood,108, 1158–1164.
Tefferi, A., Thiele, J., Orazi, A., et al. (2007). Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythaemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert. Blood, 110, 1092-1097.
Tefferi, A., & Vardiman, J. W. (2008). Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia, 22, 14–22.
Tefferi, A., Lasho, T.L., Huang, J., et al. (2008) Low JAK2V617F allele burden in primary myelofibrosis compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukaemia-free survival. Leukemia, 22, 756–761.
Tefferi, A. (2011). Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythaemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and managementol. American Journak Hematology, 86, 292-301.
Tefferi, A., & Barbui, T. (2015). Essential Thrombocythemia and Polycythaemia Vera: Focus on Clinical Practice. Mayo clinic proceedings, 90 (9), 1283-1293.
Tefferi, A., & Pardanani, A. (2015). Myeloproliferative Neoplasms: A Contemporary Review. JAMA Oncology, 1 (1), 97-105.
Tefferi, A., Vannucchi, A. M., Barbui, T., et al. (2018a). Essential thrombocythemia treatment algorithm 2018. Blood Cancer, 8 (1), 2.
Tefferi, A., Vannucchi, A. M., Barbui, T., et al. (2018b). Polycythaemia vera treatment algorithm 2018. Blood Cancer Journal, 8 (1), 3.
Tefferi, A., Vannucchi, A. M., Barbui, T., et al. (2021). Polycythaemia vera: historical oversights, diagnostic details, and therapeutic views. Leukemia, 12 (2), 339-351.
Thapaliya, P., Tefferi, A., Pardanani, A., (2011) International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisolone based regimens. American Journal of Hematology. 86, 96–98.
Thiele, J., Kvasnicka, H.M., Tefferei, A., et al. (2008) Primary myelofibrosis. In: WHO Classification of tumours of Haematopoietic and Lymphoid Tissues (eds S.H. Swerdlow, E. Campo, N.L. Harris, E. Jaffe, S.A. Pileri, H. Stein, J. Thiele&J.W. Vardiman), pp. 44–47. IARC, Lyon
Thompson, P. A., Kantarjian, H., & Cortes, J. E. (2017). Diagnosis and Treatment of Chronic Myeloid Leukemia (CML) in 2015. Mayo Clin Proc, 90 (10), 1440–1454.
Vannucchi, A.M., Antonioli, E., Guglielmelli, P., et al. (2007) Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythaemia vera or essential thrombocythemia. Blood, 110, 840–846.
Vannucchi, A. M. (2015). Ruxolitinib versus standard therapy for the treatment of polycythaemia vera. New England Journal Medicine, 372 (17), 1670-1671.
Vannucchi, A. M., & Guglielmelli, P. (2017). What are the current treatment approaches for patients with polycythaemia vera and essential thrombocythemia? Hematology American Society Hematology Education Program, 2017 (1), 480-488.
Vaquez, H. (1892). On a special form of cyanosis accompanied by excessive and persistent erythrocytosis. Comp Rend Soc Biol, 12, 384-388.
Weinfeld, A., Swolin, B., Westin, J., et al. (1994). Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications. European Journal Haematolgy, 52 (3), 134-139.
Wiest, R., Strauch, U., Wagner, H., et al. G. (2004) A patient with myelofibrosis complicated by refractory ascites and portal hypertension: to tips or not to tips? A case report with discussion of the mechanism of ascites formation. Scandinavian Journal of Gastroenterology, 39, 389–394.
Wilkins, B.S., Erber, W.N., Bareford, D., et al. (2008) Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood, 111, 60–70.
Copyright (c) 2023 Lukman Haruna, Yazid Bello, Abdulrahman Yakubu, Aliyu Garba, Ibrahim Kalle Kwaifa, Festus Ouigwe, Ibrahim Aliyu Bagudo, Hauwa Buhari Ali, Muhammad Sani Kasimu, Sani Lawal Sani
This work is licensed under a Creative Commons Attribution 4.0 International License.
